Multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) is one of the most fascinating mid-cap healthcare stocks on the market. Usually, when a company misses a primary endpoint in a landmark trial, it’s time to fold the hand and focus on the next one. The reality is that many investors did just that, and the stock is down more than 30% in 2026 as I write. Still, there’s a case building for its MCED test to receive approval from the Food and Drug Administration (FDA) and coverage from medical insurers. Here’s what you need to know before investing in the stock.
Grail’s Galleri test
The Galleri MCED test is intended to detect more than 50 cancers at an early stage, and in doing so, improve patient outcomes while significantly reducing treatment costs — late-stage cancers (III and IV) are far more costly and invasive to treat. To demonstrate Galleri’s…




